Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Sep 1, 2011 → Oct 1, 2011
NCT ID
NCT01430091About Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])
Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT]) is a phase 1 stage product being developed by Eli Lilly for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01430091. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01430091 | Phase 1 | Completed |
Competing Products
20 competing products in Sickle Cell Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prasugrel + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 33 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel | Daiichi Sankyo | Phase 2 | 52 |
| Lexiscan | Astellas Pharma | Phase 1 | 33 |
| Placebo + Dalteparin | Eisai | Phase 2 | 52 |
| tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Lidocaine Iv + Placebo | Johnson & Johnson | Phase 2 | 52 |
| ICA-17043 | Johnson & Johnson | Phase 3 | 77 |
| Ticagrelor | AstraZeneca | Phase 1 | 33 |
| Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet) | AstraZeneca | Phase 1 | 33 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Placebo | AstraZeneca | Phase 3 | 77 |
| Brilinta + Placebo | AstraZeneca | Phase 3 | 77 |
| Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b | AstraZeneca | Phase 2 | 52 |
| vorinostat | Merck | Phase 2 | 52 |
| Crizanlizumab + Placebo | Novartis | Phase 3 | 77 |
| Crizanlizuamb + Standard of Care | Novartis | Phase 2 | 52 |
| Crizanlizumab | Novartis | Approved | 85 |
| Hydroxyurea | Novartis | Phase 3 | 77 |